Vaccine

Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference

CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today…

2 years ago

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program

COPENHAGEN, Denmark, May 17, 2023 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced…

2 years ago

Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)

Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics ApplicationsSAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Telesis Bio…

2 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning…

2 years ago

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing…

2 years ago

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,…

2 years ago

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage…

2 years ago

Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s…

2 years ago

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel…

2 years ago

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins…

2 years ago